Drug intelligence / Profile preview

NC-ANGB01

Development stage: Preclinical
Lead developer: NodCure

Overview

NC-ANGB01 is a veterinary oncology drug candidate under development by the South Korean biotechnology company NodCure. While NodCure primarily focuses on human microbiome-derived therapeutics, NC-ANGB01 is a distinct program targeting cancer in veterinary patients. The asset is currently in the preclinical development phase, with the company working toward establishing clinical proof-of-concept. The specific mechanism of action and molecular targets have not been publicly detailed, though the nomenclature suggests a potential role in inhibiting angiogenesis.

Beyond the preview

Go deeper on NC-ANGB01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NC-ANGB01.

Explore the full profile